BSX
BULLISH
$59.52
Live
Boston Scientific Corporation · NYSE
Target $96.66
(+62.4%)
$59.38
52W Range
$109.5
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 22, 2026
Market cap
$88.46B
P/E
31.49
ROE
12.4%
Profit margin
14.4%
Debt/Equity
0.49
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
BSX presents a classic divergence between deteriorating technicals and strong fundamental growth. While the Piotroski F-Score of 4/9 indicates stable but not exceptional financial health, the company exhibits robust revenue (15.9%) and earnings (18.5%) growth. The stock is currently trading near its growth-based intrinsic value ($55.75) and significantly below analyst targets ($96.66), with a highly attractive PEG ratio of 0.66 suggesting undervaluation relative to growth. Despite a severe 6-month price decline, the consistent track record of earnings beats and a low Forward P/E (15.26) support a bullish long-term outlook.
Key Strengths
Strong double-digit revenue and earnings growth (YoY)
Highly attractive PEG ratio (0.66) indicating growth is underpriced
Consistent history of beating quarterly earnings estimates
Healthy balance sheet with low Debt/Equity (0.49) and solid Current Ratio (1.62)
Significant gap between current price ($59.52) and analyst target price ($96.66)
Key Risks
Severe negative technical momentum (1Y change -36.4%, 6M change -40.4%)
High current P/E ratio (31.49) compared to historical value benchmarks
Lack of dividend yield provides no floor for income-seeking investors
Significant discrepancy between Graham Number ($26.36) and current market price
Potential sector-specific headwinds causing the recent sharp price correction
AI Fair Value Estimate
Based on comprehensive analysis
$68.5
+15.1% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
51
Moderate
60
90
45
60
0
AI Verdict
Fundamental Value Play
Key drivers: Earnings growth, PEG ratio, Analyst targets, Technical breakdown
Confidence
80%
Value
60/100
P/E 31.49, PEG 0.66, Graham $26.36
Positives
- Low PEG ratio
- Low Forward P/E
Watchpoints
- Trades well above Graham Number
- High current P/E
Future
90/100
Ref Growth rates and Analyst Target $96.66
Positives
- 15.9% Revenue Growth
- 18.5% Earnings Growth
- Strong analyst target price
Watchpoints
- Market sentiment is currently bearish
Past
45/100
Ref Historical price trends and Earnings track record
Positives
- Consistent EPS beats over 25 quarters
Watchpoints
- Severe 1-year price decline (-36.4%)
- Poor 6-month momentum
Health
60/100
Ref Piotroski F-Score and Debt/Equity
Positives
- Low Debt/Equity (0.49)
- Current Ratio 1.62
Watchpoints
- Piotroski F-Score 4/9 is only 'Stable'
Dividend
0/100
Ref Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0% Payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$59.52
Analyst Target
$96.66
Upside/Downside
+62.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BSX and closest competitors.
Updated 2026-04-21
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corporation
Primary
|
+39.8% | +16.4% | -36.4% | -40.4% | -14.4% | -6.7% |
|
CVS
CVS Health Corporation
Peer
|
+14.8% | +6.9% | +10.6% | -4.2% | -11.3% | +0.3% |
|
REGN
Regeneron Pharmaceuticals, Inc.
Peer
|
+63.8% | -5.3% | +22.5% | +37.8% | -2.3% | +4.2% |
|
MCK
McKesson Corporation
Peer
|
+373.0% | +141.7% | +38.6% | +16.5% | +6.3% | -1.2% |
|
ELV
Elevance Health, Inc.
Peer
|
-7.3% | -23.6% | -17.6% | -5.1% | +13.4% | +4.7% |
BSX
Boston Scientific Corporation
Primary
5Y
+39.8%
3Y
+16.4%
1Y
-36.4%
6M
-40.4%
1M
-14.4%
1W
-6.7%
CVS
CVS Health Corporation
Peer
5Y
+14.8%
3Y
+6.9%
1Y
+10.6%
6M
-4.2%
1M
-11.3%
1W
+0.3%
REG
Regeneron Pharmaceuticals, Inc.
Peer
5Y
+63.8%
3Y
-5.3%
1Y
+22.5%
6M
+37.8%
1M
-2.3%
1W
+4.2%
MCK
McKesson Corporation
Peer
5Y
+373.0%
3Y
+141.7%
1Y
+38.6%
6M
+16.5%
1M
+6.3%
1W
-1.2%
ELV
Elevance Health, Inc.
Peer
5Y
-7.3%
3Y
-23.6%
1Y
-17.6%
6M
-5.1%
1M
+13.4%
1W
+4.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
31.49
Forward P/E
15.26
PEG Ratio
0.66
P/B Ratio
3.64
P/S Ratio
4.41
EV/Revenue
4.91
EV/EBITDA
18.46
Market Cap
$88.46B
Profitability
Profit margins and return metrics
Profit Margin
14.44%
Operating Margin
19.69%
Gross Margin
68.78%
ROE
12.45%
ROA
5.98%
Growth
Revenue and earnings growth rates
Revenue Growth
+15.9%
Earnings Growth
+18.5%
Q/Q Revenue Growth
+15.9%
Q/Q Earnings Growth
+18.9%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.49
Low debt
Current Ratio
1.62
Good
Quick Ratio
0.9
Poor
Cash/Share
$1.32
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$5.3B
Gross Margin
69.6%
Op. Margin
19.7%
Net Margin
12.7%
Total Assets
$43.7B
Liabilities
$19.2B
Equity
$24.2B
Debt/Equity
0.79x
Operating CF
$1.4B
CapEx
$-0.4B
Free Cash Flow
$0.9B
FCF Yield
69%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-22
$N/A
2026-02-04
$0.8
+2.4% surprise
2025-10-22
$0.75
+5.1% surprise
2025-07-23
$0.53
+9.7% surprise
Healthcare Sector Comparison
Comparing BSX against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
31.49
This Stock
vs
75.44
Sector Avg
-58.3%
(Discount)
Return on Equity (ROE)
12.45%
This Stock
vs
-88.14%
Sector Avg
-114.1%
(Below Avg)
Profit Margin
14.44%
This Stock
vs
-16.28%
Sector Avg
-188.7%
(Weaker)
Debt to Equity
0.49
This Stock
vs
2.66
Sector Avg
-81.6%
(Less Debt)
Revenue Growth
15.9%
This Stock
vs
124.04%
Sector Avg
-87.2%
(Slower)
Current Ratio
1.62
This Stock
vs
4.47
Sector Avg
-63.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corporation
|
BULLISH | $88.46B | 31.49 | 12.4% | 14.4% | $59.52 | |
|
CVS
CVS Health Corporation
|
BEARISH | $92.15B | 52.11 | 2.3% | 0.4% | $72.44 | Compare |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
NEUTRAL | $81.68B | 18.61 | 14.9% | 31.4% | $772.64 | Compare |
|
MCK
McKesson Corporation
|
BULLISH | $104.45B | 26.32 | -% | 1.0% | $842.09 | Compare |
|
ELV
Elevance Health, Inc.
|
NEUTRAL | $72.42B | 13.02 | 13.2% | 2.8% | $328.11 | Compare |
BSX
Boston...
BULLISH
Mkt Cap
$88.5B
P/E
31.5
ROE
12.4%
Price
$59.52
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | MORANO SUSAN E. | Director | Stock Award | 24 | - |
| 2026-03-02 | WEBER CHRISTOPHE PIERRE | Director | Stock Award | 879 | - |
| 2026-02-27 | WOODWORTH EMILY | Officer | Stock Award | 838 | - |
| 2026-02-13 | FITZGERALD JOSEPH MICHAEL | Officer | Stock Award | 69,796 | - |
| 2026-02-13 | FITZGERALD JOSEPH MICHAEL | Officer | Stock Award | 11,119 | - |
| 2026-02-13 | MONSON JONATHAN R | Chief Financial Officer | Stock Award | 3,814 | - |
| 2026-02-13 | BROWN VANCE R | General Counsel | Stock Award | 29,608 | - |
| 2026-02-13 | BROWN VANCE R | General Counsel | Stock Award | 4,808 | - |
| 2026-02-13 | WOODWORTH EMILY | Officer | Stock Award | 2,711 | - |
| 2026-02-13 | O'SULLIVAN MIRIAM | Officer | Stock Award | 2,702 | - |
| 2026-02-13 | O'CONNOR PADRAIG ANDREW | Officer | Stock Award | 2,595 | - |
| 2026-02-13 | MAHONEY MICHAEL F | Chief Executive Officer | Stock Award | 264,380 | - |
| 2026-02-13 | MAHONEY MICHAEL F | Chief Executive Officer | Stock Award | 41,621 | - |
| 2026-02-13 | BUTCHER ARTHUR C | Officer | Stock Award | 50,760 | - |
| 2026-02-13 | BUTCHER ARTHUR C | Officer | Stock Award | 7,956 | - |
MORANO SUSAN E.
Director
2026-03-02
24 shares
WEBER CHRISTOPHE PIERRE
Director
2026-03-02
879 shares
WOODWORTH EMILY
Officer
2026-02-27
838 shares
FITZGERALD JOSEPH MICHAEL
Officer
2026-02-13
69,796 shares
FITZGERALD JOSEPH MICHAEL
Officer
2026-02-13
11,119 shares
MONSON JONATHAN R
Chief Financial Officer
2026-02-13
3,814 shares
BROWN VANCE R
General Counsel
2026-02-13
29,608 shares
BROWN VANCE R
General Counsel
2026-02-13
4,808 shares
WOODWORTH EMILY
Officer
2026-02-13
2,711 shares
O'SULLIVAN MIRIAM
Officer
2026-02-13
2,702 shares
O'CONNOR PADRAIG ANDREW
Officer
2026-02-13
2,595 shares
MAHONEY MICHAEL F
Chief Executive Officer
2026-02-13
264,380 shares
MAHONEY MICHAEL F
Chief Executive Officer
2026-02-13
41,621 shares
BUTCHER ARTHUR C
Officer
2026-02-13
50,760 shares
BUTCHER ARTHUR C
Officer
2026-02-13
7,956 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
DEF 14A
8-K
8-K
10-K
8-K
8-K
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
32 analysts
Stifel
2026-04-21
Buy
Buy
Truist Securities
2026-04-15
Buy
Buy
Mizuho
2026-04-13
Outperform
Outperform
Citigroup
2026-04-07
Buy
Buy
Evercore ISI Group
2026-04-06
Outperform
Outperform
RBC Capital
2026-03-30
Outperform
Outperform
Raymond James
2026-03-30
Strong Buy
Outperform
Needham
2026-03-30
Buy
Buy
Goldman Sachs
2026-03-27
Buy
Buy
Stifel
2026-03-20
Buy
Buy
Past News Coverage
Recent headlines mentioning BSX from our newsroom.
Newest → oldest
No matching news yet.